1.79
+0.14(+8.48%)
Currency In USD
| Previous Close | 1.65 |
| Open | 1.66 |
| Day High | 1.85 |
| Day Low | 1.66 |
| 52-Week High | 9.84 |
| 52-Week Low | 1.6 |
| Volume | 77,106 |
| Average Volume | 147,743 |
| Market Cap | 11.02M |
| PE | -1.24 |
| EPS | -1.44 |
| Moving Average 50 Days | 2.47 |
| Moving Average 200 Days | 3.79 |
| Change | 0.14 |
If you invested $1000 in Chemomab Therapeutics Ltd. (CMMB) since IPO date, it would be worth $2.59 as of January 05, 2026 at a share price of $1.79. Whereas If you bought $1000 worth of Chemomab Therapeutics Ltd. (CMMB) shares 5 years ago, it would be worth $14.64 as of January 05, 2026 at a share price of $1.79.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
GlobeNewswire Inc.
Dec 02, 2025 1:00 PM GMT
—New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a Phase 3 Registration Trial— TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Chemoma
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Nov 20, 2025 1:00 PM GMT
—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a Clinical Event Composite Endpoint— —Phase 2 SPRING Tria
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
GlobeNewswire Inc.
Nov 06, 2025 1:00 PM GMT
— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks— —New Clinical Data Provides Insights on Nebokitug’s Direct Macrophage-Mediate